Kidney Cancer (Renal Cell Cancer) - Pipeline Review, H1 2020

Kidney Cancer (Renal Cell Cancer) - Pipeline Review, H1 2020



latest Pharmaceutical and Healthcare disease pipeline guide Kidney Cancer - Pipeline Review, H1 2020, provides an overview of the Kidney Cancer (Oncology) pipeline landscape.

Kidney cancer also called renal cancer is a disease in which kidney cells become malignant (cancerous) and grows out of control, forming a tumor. Symptoms include blood in urine, loss of appetite, fever that lasts for weeks, extreme fatigue, and anemia, shortness of breath and bone pain. Treatment includes surgery, radiation therapy and chemotherapy.

Report Highlights

Pharmaceutical and Healthcare latest pipeline guide Kidney Cancer - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Kidney Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Kidney Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Kidney Cancer (Renal Cell Cancer) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 1, 20, 162, 156, 2, 12, 101, 11 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 14, 8, 1, 16 and 1 molecules, respectively.

Kidney Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Kidney Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Kidney Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Kidney Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Kidney Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Kidney Cancer (Oncology)

Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Kidney Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Kidney Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Introduction
Kidney Cancer - Overview
Kidney Cancer - Therapeutics Development
Kidney Cancer - Therapeutics Assessment
Kidney Cancer - Companies Involved in Therapeutics Development
Kidney Cancer - Drug Profiles
Kidney Cancer - Dormant Projects
Kidney Cancer - Discontinued Products
Kidney Cancer - Product Development Milestones
Appendix

List Of Tables


Number of Products under Development for Kidney Cancer (Renal Cell Cancer), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Kidney Cancer (Renal Cell Cancer) - Pipeline by 4D Pharma Plc, H1 2020
Kidney Cancer (Renal Cell Cancer) - Pipeline by 4SC AG, H1 2020
Kidney Cancer (Renal Cell Cancer) - Pipeline by Aadi Bioscience Inc, H1 2020
Kidney Cancer (Renal Cell Cancer) - Pipeline by AbbVie Inc, H1 2020
Kidney Cancer (Renal Cell Cancer) - Pipeline by ABL Bio Inc, H1 2020
Kidney Cancer (Renal Cell Cancer) - Pipeline by Acepodia Biotech Inc, H1 2020
Kidney Cancer (Renal Cell Cancer) - Pipeline by Acrotech Biopharma LLC, H1 2020
Kidney Cancer (Renal Cell Cancer) - Pipeline by Actuate Therapeutics Inc, H1 2020
Kidney Cancer (Renal Cell Cancer) - Pipeline by Adaptimmune Therapeutics Plc, H1 2020
Kidney Cancer (Renal Cell Cancer) - Pipeline by ADC Therapeutics SA, H1 2020
Kidney Cancer (Renal Cell Cancer) - Pipeline by Adlai Nortye Biopharma Co Ltd, H1 2020
Kidney Cancer (Renal Cell Cancer) - Pipeline by Advenchen Laboratories LLC, H1 2020
Kidney Cancer (Renal Cell Cancer) - Pipeline by Affimed GmbH, H1 2020
Kidney Cancer (Renal Cell Cancer) - Pipeline by Affitech A/S, H1 2020
Kidney Cancer (Renal Cell Cancer) - Pipeline by Agenus Inc, H1 2020
Kidney Cancer (Renal Cell Cancer) - Pipeline by AIM ImmunoTech Inc, H1 2020
Kidney Cancer (Renal Cell Cancer) - Pipeline by Akeso Inc, H1 2020
Kidney Cancer (Renal Cell Cancer) - Pipeline by Alkermes Plc, H1 2020
Kidney Cancer (Renal Cell Cancer) - Pipeline by Alligator Bioscience AB, H1 2020

List Of Figures


Number of Products under Development for Kidney Cancer (Renal Cell Cancer), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020

Anemia in Chronic Kidney Disease (Renal Anemia) Global Clinical Trials Review, H1, 2020

Anemia in Chronic Kidney Disease (Renal Anemia) Global Clinical Trials Review, H1, 2020 clinical trial report, Anemia in Chronic Kidney Disease (Renal Anemia) Global Clinical Trials Review, H1, 2020 provides

USD 2500 View Report

Acute Renal Failure (ARF) (Acute Kidney Injury) Global Clinical Trials Review, H1, 2020

Acute Renal Failure (ARF) (Acute Kidney Injury) Global Clinical Trials Review, H1, 2020 clinical trial report, Acute Renal Failure (ARF) (Acute Kidney Injury) Global Clinical Trials Review, H1, 2020 provides

USD 2500 View Report

Kidney Cancer Drugs Global Market Report 2020

Kidney Cancer Drugs Market Global Report 2020 provides strategists, marketers and senior management with the critical information they need to assess the global kidney cancer drugs market.Reasons to Purchase Gain

USD 4000 View Report

Global Kidney Cancer Diagnostics And Therapeutics Market Report 2019, Competitive Landscape, Trends and Opportunities

The Kidney Cancer Diagnostics And Therapeutics market has witnessed growth from USD XX million to USD XX million from 2014 to 2019. With the CAGR of X.X%, this market is

USD 2950 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available